

# Metabolic Substrate Support and Tight Glycaemic control in Abdominal Aortic Aneurysm (AAA) Repair

<b>Submission date</b> 30/09/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 30/09/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 19/08/2015	<b>Condition category</b> Surgery	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr R K Vohra

**Contact details**  
Vascular Surgery  
Selly Oak Hospital  
Birmingham  
United Kingdom  
B29 6JD  
+44 (0)121 627 1627  
abc@email.com

## Additional identifiers

**Protocol serial number**  
N0265126499

## Study information

**Scientific Title**

# Metabolic Substrate Support and Tight Glycaemic control in Abdominal Aortic Aneurysm (AAA) Repair

## Study objectives

It is hypothesised that glucose-insulin-potassium (GIK) solution will reduce the incidence of perioperative myocardial ischaemia and attenuate the inflammatory response associated with AAA repair. It is further hypothesised that there will be a proportion of patients undergoing abdominal non vascular surgery in which there is cardiac and skeletal muscle damage and systemic inflammation detected. This proportion is however hypothesised to be less than in AAA repair.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Surgery: Abdominal aortic aneurysm (AAA) repair

## Interventions

Patients are randomised to receive either glucose-insulin-potassium or ALK or normal saline solution.

Specimen collection in Theatre. Selly Oak Hospital Intensive Therapy Unit (ITU) and on Selly Oak Hospital Vascular Ward. Blood (10 ml) and urine (5 ml from catheter bag) samples will be collected pre-operatively, during the procedure and at intervals up to 3 days postoperatively. In total, 5 sets of blood and 8 sets of urine specimens will be collected per patient. Blood will be collected from an arterial line or central line and will rarely involve additional venepuncture. Cardiac and inflammatory markers measured on these samples will include cardiac Troponin I, total Creatine Kinase (CK), CK myocardial band (CK-MB) fraction, C-reactive protein (CRP), interleukin 6 (IL6) and urinary microalbumin.

In addition, hourly monitoring of arterial blood gases, glucose, lactate and potassium will be taken from commencement of study solution until 6 hours following completion of study solution infusion. This will involve 15 x ml blood samples taken painlessly from an arterial line and ensures the safety of the study.

## Femoral Venous Blood Sampling in Theatre and Selly Oak Hospital ITU

Blood (5 ml) will be collected before surgery, during surgery and up to 24 hours following surgery. In total 5 sets of specimens will be collected per patient. This is a technique of blood taking that is widely employed by medical staff in hospitals when patients have poor arm veins for phlebotomy. Risks of the procedure are as for normal blood taking, i.e. a bruise.

## Gastric tonometry

After induction of anaesthesia, a gastric tonometer will be inserted by the surgical research fellow to monitor the splanchnic perfusion. This is an adapted nasogastric tube which has gastric pH monitoring capabilities. A nasogastric tube is normally placed in all patients undergoing AAA repair.

## Intervention Type

Drug

## Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Glucose-insulin-potassium

## Primary outcome(s)

A reduction in cardiac Troponin I release of 0.75 standard deviations from the mean in the GIK group compared with the control group.

## Key secondary outcome(s)

Secondary (in GIK group) - Reduced cardiac ischaemia as measured by electrocardiogram (ECG), creatinine kinase (CK) total and CK-MB, reduced inflammatory response as measured by IL6, CRP, gastric tonometry - reduced Intensive Therapy Unit (ITU) stay, intubation time.

## Completion date

05/09/2008

## Eligibility

### Key inclusion criteria

60 patients requiring elective infra-renal aortic surgery for aneurysm disease will be recruited over 18 months in the Department of Vascular Surgery. All 60 patients will be randomised to receive the "study solution" either ALK or normal saline control.

A further group of 30 patients (age and sex matched controls) undergoing elective abdominal, non vascular surgery will also be studied. They will not have any therapeutic interventions but will be managed as per usual by the medical teams looking after them. Cardiac and skeletal muscle damage and systemic inflammation will be measured in these patients for up to 5 days post operatively.

### Participant type(s)

Patient

### Healthy volunteers allowed

No

### Age group

Adult

### Lower age limit

18 years

**Sex**

All

**Key exclusion criteria**

1. Pregnancy
2. Patients <18 years old
3. Patients with Diabetes Mellitus
4. Patients who have not given informed consent
5. Patients who are unable to give informed consent
6. Patients with a preoperative haemoglobin of <11 g/dl
7. Patients undergoing emergency surgery for ruptured abdominal aortic aneurysm
8. Patients with a history of sensitivity reaction to the solutions under study
9. Patients participating in another study
10. Patients with renal impairment. creatinine >200 gmol/l

**Date of first enrolment**

05/09/2003

**Date of final enrolment**

05/09/2008

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

Selly Oak Hospital

Birmingham

United Kingdom

B29 6JD

**Sponsor information****Organisation**

Department of Health

**Funder(s)****Funder type**

Government

**Funder Name**

University Hospital Birmingham NHS Trust (UK)

**Results and Publications****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration